June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Effect of adalimumab on visual functioning (VFQ-25) in VISUAL-1 trial patients with non-anterior non-infectious uveitis
Author Affiliations & Notes
  • John D Sheppard
    Ophthalmology, Eastern Virginia Medical Sch, Norfolk, VA
    Virginia Eye Consultants, Norfolk, VA
  • Avani Joshi
    AbbVie, North Chicago, IL
  • Manish Mittal
    AbbVie, North Chicago, IL
  • Keith Betts
    Analysis Group, Boston, MA
  • Samir R Tari
    AbbVie, North Chicago, IL
  • Yanjun Bao
    AbbVie, North Chicago, IL
  • Andrew D Dick
    University of Bristol, Bristol, United Kingdom
  • Footnotes
    Commercial Relationships John Sheppard, Abbvie (C), Alcon (C), Aldeyra (C), Allergan (C), Bausch & Lomb (C), EyeGate (C), EyeGate (I); Avani Joshi, AbbVie (E); Manish Mittal, AbbVie (E); Keith Betts, Analysis Group (F); Samir Tari, AbbVie (E); Yanjun Bao, AbbVie (E); Andrew Dick, Abbvie (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1723. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      John D Sheppard, Avani Joshi, Manish Mittal, Keith Betts, Samir R Tari, Yanjun Bao, Andrew D Dick, IM; Effect of adalimumab on visual functioning (VFQ-25) in VISUAL-1 trial patients with non-anterior non-infectious uveitis. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1723.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To compare the effects of adalimumab and placebo on the National Eye Institute Visual Functioning Questionnaire 25 (VFQ-25) in subjects requiring high dose corticosteroids for active non-infectious intermediate-, posterior-, or pan-uveitis.


The VISUAL-1 clinical trial (NCT01148225) was a phase 3, randomized placebo-controlled study. It investigated the efficacy and safety of adalimumab (80 mg loading dose followed by 40 mg every other week) as maintenance therapy in subjects with active non-infectious intermediate-, posterior- or pan-uveitis. The VFQ-25 is a validated measure for assessing the impact of visual impairment from the patient’s perspective. The VFQ-25 total score is calculated as the mean of 11 vision-related domains and scores range from 0 (worst vision functioning) to 100 (best vision functioning). The VFQ-25 was administered at every scheduled study visit of the 80 Week trial. As a ranked secondary outcome, the change in VFQ-25 from best state achieved prior to Week 6 to the final / early termination visit was compared between adalimumab and placebo using ANOVA. To investigate the temporal effects of adalimumab and placebo on VFQ-25 in a robust manner, a longitudinal GEE model (which incorporated all VFQ-25 measurements) was estimated.


The VISUAL-1 clinical trial enrolled a total of 217 subjects (110 adalimumab, 107 placebo). The mean VFQ-25 total scores for adalimumab and placebo are similar through the tapering period but subsequently diverge and maintain separation through week 80 (Figure 1). The average change in VFQ-25 total score from best state achieved prior to Week 6 to the final / early termination visit was -5.50 for placebo and -1.30 for adalimumab. This corresponds to a statistically significant and clinically meaningful1 increase of 4.20 (95% confidence interval [CI]: 1.02 - 7.38; P = 0.010) associated with adalimumab relative to placebo. The longitudinal model estimated a statistically significant treatment effect of adalimumab of 3.07 (95% CI: 2.09 - 4.06; P<0.001).


Treatment with adalimumab is associated with statistically significant improvements in visual functioning for subjects with active non-infectious non-anterior uveitis.  

Figure 1: Mean VFQ-25 over time
Figure 1: Mean VFQ-25 over time


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.